Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death

Molecular Cancer Therapeutics

Volumn 12, Issue 5, 2013, Pages 768-776

  Ambrosini, Grazia ^a,b   Musi, Elgilda ^a   Ho, Alan L ^a   De Stanchina, Elisa ^b   Schwartz, Gary K ^a  

^a Laboratory of New Drug Development   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; B RAF KINASE; BECLIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN Q POLYPEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SELUMETINIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE MUTATION; GENOTYPE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UVEA MELANOMA;

ANIMALS; AUTOPHAGY; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; GTP-BINDING PROTEIN ALPHA SUBUNITS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR BURDEN; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877642623     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1020     Document Type: Article

References (44)

1. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:5230-4.
2. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
3. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
4. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92:2032-8.
5. Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, et al. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:23-7.
6. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:962-5.
7. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44: 4651-9.
8. Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 2011;52:7248-55.
9. Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res 2012;18:1-10.
10. Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, et al. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 2009;8:2073-80.
11. Little AS, Balmanno K, Sale MJ, Smith PD, Cook SJ. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochem Society Trans 2012;40:73-8.
12. Rozengurt E. Mitogenic signaling pathways induced by G proteincoupled receptors. J Cell Physiol 2007;213:589-602.
13. Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. Activation of Akt/protein kinase Bby Gprotein-coupled receptors. Arole for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol- 3-OH kinasegamma. J Biol Chem 1998;273: 19080-5.
14. Golebiewska U, Scarlata S. Galphaq binds two effectors separately in cells: evidence for predetermined signaling pathways. Biophys J 2008;95:2575-82.
15. Ballou LM, Chattopadhyay M, Li Y, Scarlata S, Lin RZ. Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. Biochem J 2006;394:557-62.
16. Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci 2010;51: 421-9.
17. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ-and GNA11-Dependent Manner. Clin Cancer Res 2012;18:4345-55.
18. Yoshimori T. Autophagy: a regulated bulk degradation process inside cells. Biochem Biophys Res Comm 2004;313:453-8.
19. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717-21.
20. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Diff 2009;16:966-75.
21. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004;304:1500-2.
22. Speirs CK, Hwang M, Kim S, Li W, Chang S, Varki V, et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res 2011;1:43-61.
23. Luyten GP, Naus NC, Mooy CM, Hagemeijer A, Kan-Mitchell J, Van Drunen E, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer 1996;66:380-7.
24. Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, et al. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009;5:184-93.
25. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
26. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS ONE 2010;5:e13026.
27. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8: 287-97.
28. Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, Codogno P, et al. AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 2006;281:34870-9.
29. Bommakanti RK, Vinayak S, Simonds WF. Dual regulation of Akt/protein kinase B by heterotrimeric G protein subunits. J Biol Chem 2000;275:38870-6.
30. Wan Y, Kurosaki T, Huang XY. Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors. Nature 1996;380:541-4.
31. Pyne NJ, Pyne S. Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow? Trends Pharmacol Sci 2011;32:443-50.
32. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16:2505-11.
33. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011;13: 1016-23.
34. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9: 563-75.
35. Hoyer-Hansen M, Jaattela M. AMP-activated protein kinase: a universal regulator of autophagy? Autophagy 2007;3:381-3.
36. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-26.
37. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
38. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-6.
39. Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A 2006;103:4952-7.
40. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS ONE 2012;7:e40439.
41. Hubbard KB, Hepler JR. Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal 2006;18:135-50.
42. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS ONE 2010;5:e14124.
43. Tolcher AW, BR, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, et al. A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244;MEK inhibitor) in patients with advanced or metastatic solid tumors. ASCO Meeting 2011;Abstract 3004.
44. Carvajal RD, AG, Wolchok JD, Chapman PB, Dickson MA, D'Angelo SP, et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. ASCO Meeting 2012; Abstract 8598.